Compare Avalanche Treasury Corporation Class A Common Stock (AVAT) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avalanche Treasury Corporation Class A Common Stock vs Bristol-Myers Squibb Co — how do they compare? Avalanche Treasury Corporation Class A Common Stock trades at $0.35 (market cap $15.33M), while Bristol-Myers Squibb Co trades at $63.93 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 8476.2× Avalanche Treasury Corporation Class A Common Stock's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Avalanche Treasury Corporation Class A Common Stock pays none. Which is the better fit depends on your goals.
| AVAT | BMY | |
|---|---|---|
Market Cap | $15.33M | $129.94B |
Sector | Financials | Health |
52-Week High | $10.75 | $65.89 |
52-Week Low | $0.30 | $42.60 |
Enterprise Value | $15.33M | $163.92B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVAT trades at $0.37, up 9.83% in the past 24 hours. The stock shows a bearish technical signal with negative cash flow from operations of -$930,710 in 2025, though net income is positive at $8.28 million. Recent news highlights its Nasdaq listing as an operating company focused on capital allocation.
The outlook is cautious due to weak operational cash flow and bearish technical indicators. Investment appeal hinges on improved profitability and cash generation. Key risks include execution challenges and market volatility.
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
